Laboratory Medicine ›› 2021, Vol. 36 ›› Issue (1): 117-118.DOI: 10.3969/j.issn.1673-8640.2021.01.025
Received:2019-10-31
Online:2021-01-30
Published:2021-02-05
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2021.01.025
| [1] | 吴仪,郑筱更. 药品不良反应报告和监测管理办法[J]. 中国药事,2004,23(4):203-205. |
| [2] | 王利军,吴洁,崔示德,等. 血小板生成素与感染相关性反应性血小板增多关系的研究[J]. 中国医师进修杂志,2012,35(25):24-26. |
| [3] | PALANDRI F,CATANI L,TESTONI N,et al.Long-term follow-up of 386 consecutive patients with essential thrombocythemia:safety of cytoreductive therapy[J]. Am J Hematol,2009,84(4):215-220. |
| [4] | 陈沈珏,李昕,刘丽华,等. 药物致继发性血小板增多症文献分析[J]. 中国药师,2017,20(9):1633-1635. |
| [5] | NORRBY S R,NEWELL P A,FAULKNER K L,et al.Safety profile of meropenem:international clinical experience based on the first 3 125 patients treated with meropenem[J]. J Antimicrob Chemother,1995,36(Suppl A):207-223. |
| [6] | WANG X,ZHANG X,ZONG Z,et al.Biapenem versus meropenem in the treatment of bacterial infections:a multicenter,randomized,controlled clinical trial[J]. Indian J Med Res,2013,138(6):995-1002. |
| [7] | LIN Y F,YANG C H,SINDY H,et al.Severe cutaneous adverse reactions related to systemic antibiotics[J]. Clin Infect Dis,2014,58(10):1377-1385. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
